IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Secondary Progressive Multiple Sclerosis
Cairo Universitymonoclonal_antibodyPhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 60/ 100
- Competitive Position
- 89/ 100
Competitive context
36 Active assets in the Secondary Progressive Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Siponimod Novartis Pharmaceuticals | Phase 4 | BBB |
Fampridine University College Dublin | Phase 4 | BBB |
bnt162 Novartis Pharmaceuticals | Phase 4 | BB |
mis416 Innate Immunotherapeutics | Phase 2 | BB |
SIMVASTATIN University College, London | Phase 3 | BB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →